Astarazeneca’Corona 19′ vaccine that the government decided to introduce Photo = Yonhap News
It will be decided on the 29th (local time) whether to approve the conditional sale of a novel coronavirus infection (Corona 19) vaccine jointly developed by multinational pharmaceutical company AstraZeneca and Oxford University in the UK.
The European Medicines Agency (EMA) is expected to hold an expert evaluation meeting today and recommend conditional marketing approval of the vaccine. If approval is recommended, the European Commission, the executive branch of the European Union, makes a final decision within a few hours, and when official approval is granted, EU member states can begin vaccination.
If officially approved, the AstraZeneca vaccine will be the third Corona 19 vaccine available in the EU for the Corona 19 vaccine developed by the US pharmaceutical company Pfizer-German Bioentech and the US Modena.
The AstraZeneca vaccine was approved for emergency use in India, Argentina, and Mexico starting in the UK on the 30th of last month. The average preventive effect of this vaccine is 70.4%, compared to 95% Pfizer and 94.5% Modena. The EU has signed a contract to purchase 400 million vaccine doses with AstraZeneca on behalf of the member states.
However, even if the vaccine is approved, the EU must resolve the issues surrounding the initial supply volume with pharmaceutical companies. When AstraZeneca announced on the 22nd that the initial supply to Europe would decrease due to a disruption in the production of the Corona 19 vaccine, the EU demanded that the UK-produced vaccine be returned to the EU, causing friction between the two sides.
Reporter Lee Song-ryul [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution